Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

NCT02564198 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02564198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02564198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
December 11, 2015
Completion date
July 16, 2019
Enrollment
29 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cns malignancies, pediatric solid tumor, recurrent tumor, refractory tumor